Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsing Remitting Multiple Sclerosis (RRMS) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

NCT02588053
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 23, 2026, 5:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

NCT01116427
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
abatacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
20
States / cities
Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 23, 2026, 5:20 AM EDT
Active, not recruiting Phase 4 Interventional

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Ofatumumab, Disease modifying treatment (DMT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Copaxone®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 23, 2026, 5:20 AM EDT
Completed No phase listed Observational

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

NCT06127095
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01707992
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 23, 2026, 5:20 AM EDT
Terminated No phase listed Observational

Adherence Trial With MS LifeLines ® Services

NCT01905527
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Jul 23, 2026, 5:20 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

NCT03085810
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
26
States / cities
Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

RNF and Betaseron® Tolerability Study

NCT00428584
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
New Formulation of rebif - human interferon beta-1a, Interferon beta -1b
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 23, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

NCT00235989
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta 1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 23, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT02222948
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Vatelizumab, Placebo (for Vatelizumab)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

NCT01185821
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 23, 2026, 5:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

NCT01695434
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2013 · Synced Jul 23, 2026, 5:20 AM EDT
Completed No phase listed Observational

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

NCT01626248
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 23, 2026, 5:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanistic Studies of Teriflunomide in RRMS

NCT03464448
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Jul 23, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, fingolimod
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 23, 2026, 5:20 AM EDT
Withdrawn Phase 4 Interventional

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

NCT02675413
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Jul 23, 2026, 5:20 AM EDT